Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Biochem. 2014 Apr;47(6):389-92. doi: 10.1016/j.clinbiochem.2014.01.006. Epub 2014 Jan 17.

Elevated telomerase activity in essential thrombocythemia with extreme thrombocytosis.

Author information

  • 1Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, China.
  • 2Department of Oncology, Asan Medical Center, Seoul, Republic of Korea.
  • 3Department of Tumor Biology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • 4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • 5Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • 6Department of Tumor Biology, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: soonlee@snu.ac.kr.

Abstract

INTRODUCTION:

We performed a comparative analysis of telomerase activity (TA) in patients with myeloproliferative neoplasm (MPN) and myelodysplastic syndrome (MDS). The relationships between TA and known prognostic factors were also analyzed.

MATERIALS AND METHODS:

A telomeric repeat amplification protocol was performed with bone marrow hematopoietic cells from 96 normal controls, 44 MPNs, and 40 MDSs.

RESULT:

TA (measured as molecules/reaction) showed no correlation with age in the control group (R(2)=0.0057, p=0.464). MPN showed elevated TA compared with controls (15,537.57 vs. 7775.44, p=0.020). Patients with essential thrombocythemia showed markedly elevated TA (22,688.56, p=0.030), particularly in cases with extreme thrombocytosis versus those without extreme thrombocytosis (34,522.19 vs. 9375.71, p=0.041). MDS patients showed a TA value of 7578.50.

CONCLUSION:

There was no association between age and TA in bone marrow hematopoietic cells. TA was elevated in MPN but borderline in MDS, probably because of differences in the nature of the diseases. Elevated TA in patients with essential thrombocythemia, especially those with extreme thrombocytosis, suggests that an anti-telomerase strategy could be beneficial in the prevention of thrombotic complications.

Copyright © 2014. Published by Elsevier Inc.

KEYWORDS:

Essential thrombocythemia; Extreme thrombocytosis; Myelodysplastic syndrome; Myeloproliferative neoplasm; Telomerase activity

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk